tumor budding positive hepatocellular carcinoma
Conditions
Interventions
Lenvatinib+losartan treatment group:Targeted+collagen degradation therapy
Sponsors
Xi'an Jiaotong University Second Affiliated Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years old, male or female not limited; 2.Histologically confirmed as hepatocellular carcinoma without metastasis; 3.Tumor budding positive; 4.The expected lifespan is at least 12 weeks;
Exclusion criteria
Exclusion criteria: 1.Hepatocellular carcinoma that cannot be surgically removed; 2.Received preoperative radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc; 3.Pregnant or lactating women; 4.Subjects with concomitant malignant tumors; 5.Researchers believe that participants who are not suitable to participate in this cohort study; 6.Subjects who refuse to be enrolled or have not signed an informed consent form; 7.Subjects with incomplete medical record information (including gender, age, diagnostic information, imaging (and) or pathological diagnosis results, other demographic data, etc.);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate within 2 years; | — |
Secondary
| Measure | Time frame |
|---|---|
| renal function;overall survival;liver function;No Recurrence Survival Time;Imaging data;Oncological Biomarkers; | — |
Countries
China
Contacts
Public ContactKai Qu
Xi'an Jiaotong University Second Affiliated Hospital
Outcome results
None listed